These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35820785)

  • 1. Dapagliflozin Prevents Kidney Glycogen Accumulation and Improves Renal Proximal Tubule Cell Functions in a Mouse Model of Glycogen Storage Disease Type 1b.
    D'Acierno M; Resaz R; Iervolino A; Nielsen R; Sardella D; Siccardi S; Costanzo V; D'Apolito L; Suzumoto Y; Segalerba D; Astigiano S; Perna AF; Capasso G; Eva A; Trepiccione F
    J Am Soc Nephrol; 2022 Oct; 33(10):1864-1875. PubMed ID: 35820785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The SGLT2 inhibitor dapagliflozin improves kidney function in glycogen storage disease XI.
    Trepiccione F; Iervolino A; D'Acierno M; Siccardi S; Costanzo V; Sardella D; De La Motte LR; D'Apolito L; Miele A; Perna AF; Capolongo G; Zacchia M; Frische S; Nielsen R; Staiano L; Sambri I; De Cegli R; Unwin R; Eladari D; Capasso G
    Sci Transl Med; 2023 Nov; 15(720):eabn4214. PubMed ID: 37910600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT5 is the renal transporter for 1,5-anhydroglucitol, a major player in two rare forms of neutropenia.
    Diederich J; Mounkoro P; Tirado HA; Chevalier N; Van Schaftingen E; Veiga-da-Cunha M
    Cell Mol Life Sci; 2023 Aug; 80(9):259. PubMed ID: 37594549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and characterization of an inducible mouse model for glycogen storage disease type Ib.
    Raggi F; Pissavino AL; Resaz R; Segalerba D; Puglisi A; Vanni C; Antonini F; Del Zotto G; Gamberucci A; Marcolongo P; Bosco MC; Grillo F; Mastracci L; Eva A
    J Inherit Metab Dis; 2018 Nov; 41(6):1015-1025. PubMed ID: 29967951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule.
    Ghezzi C; Yu AS; Hirayama BA; Kepe V; Liu J; Scafoglio C; Powell DR; Huang SC; Satyamurthy N; Barrio JR; Wright EM
    J Am Soc Nephrol; 2017 Mar; 28(3):802-810. PubMed ID: 27620988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane.
    Chichger H; Cleasby ME; Srai SK; Unwin RJ; Debnam ES; Marks J
    Exp Physiol; 2016 Jun; 101(6):731-42. PubMed ID: 27164183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose cotransporter 2 inhibition suppresses HIF-1α-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice.
    Cai T; Ke Q; Fang Y; Wen P; Chen H; Yuan Q; Luo J; Zhang Y; Sun Q; Lv Y; Zen K; Jiang L; Zhou Y; Yang J
    Cell Death Dis; 2020 May; 11(5):390. PubMed ID: 32444604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on gluconeogenesis in proximal renal tubules.
    Kim JH; Ko HY; Wang HJ; Lee H; Yun M; Kang ES
    Diabetes Obes Metab; 2020 Mar; 22(3):373-382. PubMed ID: 31692240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule.
    Pessoa TD; Campos LC; Carraro-Lacroix L; Girardi AC; Malnic G
    J Am Soc Nephrol; 2014 Sep; 25(9):2028-39. PubMed ID: 24652792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 mediates glucose reabsorption in the early proximal tubule.
    Vallon V; Platt KA; Cunard R; Schroth J; Whaley J; Thomson SC; Koepsell H; Rieg T
    J Am Soc Nephrol; 2011 Jan; 22(1):104-12. PubMed ID: 20616166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo expression of sodium-glucose cotransporter SGLT2 in Bowman's capsule coincides with replacement of parietal epithelial cell layer with proximal tubule-like epithelium.
    Tabatabai NM; North PE; Regner KR; Kumar SN; Duris CB; Blodgett AB
    J Membr Biol; 2014 Aug; 247(8):675-83. PubMed ID: 24906870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DBS are suitable for 1,5-anhydroglucitol monitoring in GSD1b and G6PC3-deficient patients taking SGLT2 inhibitors to treat neutropenia.
    Dewulf JP; Chevalier N; Marie S; Veiga-da-Cunha M
    Mol Genet Metab; 2023 Nov; 140(3):107712. PubMed ID: 38353183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SGLT2-inhibitor dapagliflozin improves neutropenia and neutrophil dysfunction in a mouse model of the inherited metabolic disorder GSDIb.
    Resaz R; Raggi F; Segalerba D; Lavarello C; Gamberucci A; Bosco MC; Astigiano S; Assunto A; Melis D; D'Acierno M; Veiga-da-Cunha M; Petretto A; Marcolongo P; Trepiccione F; Eva A
    Mol Genet Metab Rep; 2021 Dec; 29():100813. PubMed ID: 34712576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders.
    Maiorana A; Tagliaferri F; Dionisi-Vici C
    Front Endocrinol (Lausanne); 2023; 14():1145111. PubMed ID: 37152929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
    Terami N; Ogawa D; Tachibana H; Hatanaka T; Wada J; Nakatsuka A; Eguchi J; Horiguchi CS; Nishii N; Yamada H; Takei K; Makino H
    PLoS One; 2014; 9(6):e100777. PubMed ID: 24960177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
    Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
    Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of endocrine system in a patient affected by glycogen storage disease 1b: speculation on the role of autoimmunity.
    Melis D; Della Casa R; Balivo F; Minopoli G; Rossi A; Salerno M; Andria G; Parenti G
    Ital J Pediatr; 2014 Mar; 40(1):30. PubMed ID: 24646511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury.
    Chang YK; Choi H; Jeong JY; Na KR; Lee KW; Lim BJ; Choi DE
    PLoS One; 2016; 11(7):e0158810. PubMed ID: 27391020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High glucose-induced Smad3 linker phosphorylation and CCN2 expression are inhibited by dapagliflozin in a diabetic tubule epithelial cell model.
    Pan X; Phanish MK; Baines DL; Dockrell MEC
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34003249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A role for tubular Na
    Onishi A; Fu Y; Patel R; Darshi M; Crespo-Masip M; Huang W; Song P; Freeman B; Kim YC; Soleimani M; Sharma K; Thomson SC; Vallon V
    Am J Physiol Renal Physiol; 2020 Oct; 319(4):F712-F728. PubMed ID: 32893663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.